Roche Diagnostics
Search Contact Legal Statement
Index Sitemap link to Roche

Press Releases 2009
Press Releases 2008
Press Releases 2007
 


28 October 2009

Roche introduces new cobas p 630 Instrument and AMPLILINK 3.3 Series Software with CE Mark

New pre-analytical solution that integrates automated primary tube handling

Roche Molecular Diagnostics (SIX: RO, ROG; OTCQX: RHHBY) announced today the availability of the cobas p 630 Instrument with CE Mark and the AMPLILINK 3.3 Series Software. The cobas p 630 Instrument and the AMPLILINK 3.3 Series Software is intended for the E.U. and countries outside the United States that accept products with the CE Mark. With this introduction, Roche has the only pre-analytical instrument that unites primary tube handling with fully automated sample preparation, amplification and detection for molecular diagnostics. The AMPLILINK 3.3 Series Software is the latest version of the widely adopted software that integrates the cobas p 630 Instrument with the market leading COBAS® AmpliPrep Instruments and COBAS® TaqMan® Analyzers.

Download PDF-File - 91 KB
2 April 2009

Roche to introduce new LightCycler® MRSA Advanced Test in the EU

New test for detection of methicillin-resistant Staphylococcus aureus for better patient care

Roche announced today that its new LightCycler® test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) is now available with the CE Mark, allowing it to be sold for clinical use in the European Union. The LightCycler® MRSA Advanced Test is a qualitative in vitro diagnostic test for the direct detection of nasal colonization with methicillin-resistant Staphylococcus aureus. The test will aid in the prevention and control of MRSA infections in healthcare settings resulting in better patient care.

Download PDF-File - 55 KB
 
© 2009, Roche Diagnostics See our Legal Statement - Privacy Policy
This website contains information on products which is targeted to a wide range of audiences and could contain product details or information otherwise not accessible or valid in your country. Please be aware that we do not take any responsibility for accessing such information which may not comply with any valid legal process, regulation, registration or usage in the country of your origin.

Roche Molecular Diagnostics operates in the U.S. as the legal entity Roche Molecular Systems, Inc.
 
Visitor Insights Survey
Welcome to Roche Molecular Diagnostics

Whether you are a first-time visitor or a frequent visitor, we would appreciate your opinion to help improve our Web site.

Would you be willing to answer a brief questionnaire? It will take less than 5 minutes.

YesNo, thanks

This questionnaire is voluntary and your use of this Web site is not conditional upon your participation.

The questionnaire does not include any health-related questions, it strictly focuses on Web-related topics. In accordance to Roche's privacy policy, your responses will be treated with the strictest of confidence and not passed on to any third parties for their marketing purposes.